Mutabon Mite (Amitriptyline Hydrochloride, Perphenazine)

Amitriptyline Hydrochloride, the active ingredient in Mutabon Mite, is a Combination (Tricyclic Antidepressant + Phenothiazine Antipsychotic) presented as an oral combination tablet for oral use. It treats major depressive disorder, anxiety disorders, schizophrenia and other psychotic disorders in adults.

GNH USA supplies Mutabon Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mutabon Mite is a combination antidepressant‑antipsychotic that acts on mood and psychotic pathways. It is indicated for several psychiatric conditions: - Major depressive disorder: alleviates depressive symptoms and improves mood. - Anxiety disorders: reduces excessive anxiety and associated physical tension. - Schizophrenia: controls psychotic symptoms such as hallucinations and delusions. - Other psychotic disorders: improves overall psychotic symptomatology.

Adverse reactions may occur with any psychiatric medication. Common side effects are usually mild and transient.

Common Side Effects: - Dry mouth: reduced salivary flow causing discomfort. - Drowsiness: increased sedation, especially after dose initiation. - Constipation: slowed gastrointestinal motility. - Weight gain: gradual increase in body weight.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe reduction in white blood cells. - Cardiac arrhythmia: abnormal heart rhythm, particularly in patients with pre‑existing heart disease.

Before prescribing Mutabon Mite, clinicians should consider several safety measures. - Cardiac monitoring: assess patients with known heart disease for arrhythmia risk. - Suicidal ideation: monitor especially during early treatment phases. - Liver function: evaluate hepatic status and adjust if impaired. - Abrupt discontinuation: taper dose under medical supervision to avoid withdrawal. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mutabon Mite can interact with a range of medicines; some combinations should be avoided.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - SSRIs or other serotonergic agents: potential serotonin syndrome. - Other anticholinergics: increased anticholinergic burden. - CNS depressants: enhanced sedation and respiratory depression. - QT‑prolonging drugs: heightened risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors: may increase amitriptyline levels. - Antihypertensives: additive blood‑pressure lowering effect. - Antidiabetic agents: possible alteration of glucose control. - Alcohol: increased sedation and dizziness. - Antihistamines: enhanced anticholinergic side effects.